Real-world use of venetoclax in the treatment of paediatric and teenage/young adult haematological malignancies

Gynecologic Cancer

Impact of patient selection on real-world outcomes by using the EMBRACE-II treatment protocol in locally advanced cervical cancer

Int J Radiat Oncol Biol Phys

Lindegaard JC, Kirisits C, Schmid MP, Wulff CN, Steen SG, Kristoffersen KB, Pötter R, Petric P

doi: 10.1016/j.ijrobp.2025.05.068

Lung, Respiratory and Thoracic Cancer

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

JTO Clin Res Rep

Schmid S, Holer L, Gysel K, Koster KL, Rothschild SI, Boos LA, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur WD, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti LA

doi: 10.1016/j.jtocrr.2024.100735

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Leukemia

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group

Leuk Lymphoma

Zielonka K, Izdebski B, Drozd-Sokołowska J, Pruszczyk-Matusiak K, Puła B, Wiśniewski K, Sawicki W, Kalicińska E, Jabłonowska-Babij P, Butrym A, Buczek T, Subocz E, Hałka J, Witkowska M, Wilk M, Hryniewiecka M, Gruenpeter K, Cichocka E, Halicki P, Wdowiak K, Iskierka-Jażdżewska E, Kopińska A, Szlauer-Stefańska A, Szymczyk A, Wolska-Washer A, Kowalczyk J, Wróbel T, Hus I, Jamroziak K

doi: 10.1080/10428194.2025.2535693

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

ASH 2024

Lymphoma

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

ASH 2024

Leukemia

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

ASH 2024

Lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study

Lung Cancer

Lee J, Kim M, Han HJ, Kim S, Suh HS

doi: 10.1016/j.lungcan.2025.108682

Related content

Impact of patient selection on real-world outcomes by using the EMBRACE-II treatment protocol in locally advanced cervical cancer

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

Results of TRODELVY® real-world data

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Real-world evidence confirms gilteritinib as an effective treatment option for R/R FLT3-mutated AML

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study

Results of TRODELVY^® real-world data